NWQ Investment Management Company LLC cut its holdings in GlaxoSmithKline plc (NYSE:GSK) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,642,926 shares of the pharmaceutical company’s stock after selling 85,532 shares during the quarter. GlaxoSmithKline makes up approximately 1.2% of NWQ Investment Management Company LLC’s portfolio, making the stock its 14th largest holding. NWQ Investment Management Company LLC owned 0.11% of GlaxoSmithKline worth $93,745,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in GSK. Field & Main Bank acquired a new stake in shares of GlaxoSmithKline in the fourth quarter valued at approximately $132,000. First Dallas Securities Inc. acquired a new stake in shares of GlaxoSmithKline in the fourth quarter valued at approximately $142,000. Wealthcare Advisory Partners LLC grew its position in shares of GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,351 shares during the last quarter. Waldron LP acquired a new stake in shares of GlaxoSmithKline in the third quarter valued at approximately $203,000. Finally, Belpointe Asset Management LLC acquired a new stake in GlaxoSmithKline during the third quarter worth approximately $204,000. Institutional investors and hedge funds own 10.98% of the company’s stock.
A number of analysts recently issued reports on GSK shares. Kepler Capital Markets upgraded shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday, February 9th. Zacks Investment Research lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Cowen restated a “hold” rating and set a $40.00 target price on shares of GlaxoSmithKline in a research report on Thursday, February 15th. ValuEngine lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, January 11th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $38.77.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.03. The company had revenue of $10.14 billion for the quarter, compared to analyst estimates of $9.89 billion. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. analysts forecast that GlaxoSmithKline plc will post 2.95 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be issued a $0.633 dividend. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.78%. The ex-dividend date of this dividend is Thursday, February 22nd. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio (DPR) is 320.26%.
COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/12/nwq-investment-management-company-llc-lowers-stake-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.